Cambrooke Therapeutics Launches KetoVie Peptide, a Groundbreaking Hydrolyzed Protein-Based Ketogenic Formula for Children with Intractable Epilepsy

AYER, Mass.--()--Cambrooke Therapeutics, Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the launch of the first and only ketogenic hydrolyzed whey-based (peptides) formula, designed for individuals on a ketogenic diet who have milk protein sensitivities and/or impaired digestive function. Because of its peptide protein formulation, KetoVie™ Peptide is ideal for tube feeding. Digestive disorders are comorbid conditions with significantly higher rates in epilepsy than the general population and often benefit from nutritional management with a peptide protein source.

Until the launch of KetoVie Peptide, ketogenic dietitians had limited options for their patients with digestive disorders requiring a hypoallergenic protein source. Ketogenic dietitian Charlotte Wehran said, “Before starting the ketogenic diet, one of my patients could only tolerate a peptide-based formula. We tried multiple failed formulas before hearing about KetoVie Peptide. The other ketogenic formulas did help decrease his seizures but with much discomfort. After trying KetoVie Peptide, my patient no longer has the abdominal discomfort, and today, he is a much healthier, happier, seizure-free toddler. We are very happy with the success we have had with KetoVie Peptide.”

KetoVie’s mission is to help bring a better quality of life to those suffering with intractable epilepsy. The patent pending KetoVie Peptide formula is a ready-to-use, nutritionally complete 4-to-1 ketogenic ratio with a hypoallergenic whey peptide protein source for individuals over one year of age. Additionally, KetoVie Peptide contains MCTs to help boost ketosis and aid digestion. To minimize digestive sensitivities, the formula does not contain fiber, artificial sweeteners, flavors or colors. In 2015, Cambrooke launched KetoVie 4:1, the first ready-to-drink whey-based (whole protein) ketogenic formula with MCT, and KetoVie Café Wholesome Bread, the first ketogenic friendly, ready-to-serve bread.

Clinicians and families can visit www.ketovie.com to learn more about new products, tools, recipes, and resources to assist families with their everyday living when on a ketogenic diet.

About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics, Inc. is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.

Contacts

Cambrooke Therapeutics, Inc.
Elayna Rucker-Byers, 301-980-6594
erucker-byers@cambrooke.com

Release Summary

Cambrooke Therapeutics Launches KetoVie Peptide, a Groundbreaking Hydrolyzed Protein-Based Ketogenic Formula for Children with Intractable Epilepsy

Contacts

Cambrooke Therapeutics, Inc.
Elayna Rucker-Byers, 301-980-6594
erucker-byers@cambrooke.com